Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eyepoint Pharmaceuticals Inc
(NQ:
EYPT
)
8.630
+0.260 (+3.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eyepoint Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Bragar Eagel & Squire, P.C. Is Investigating Vintage Wine, Flowserve, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
October 31, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating FedEx, Cantaloupe, Compass, and EyePoint and Encourages Investors to Contact the Firm
October 27, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, F45 Training, and PROG and Encourages Investors to Contact the Firm
October 26, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
EyePoint Pharma Posts 12-Month Safety, Efficacy Data From Early-Stage Wet AMD Trial
July 15, 2022
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
October 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
October 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm
October 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock
July 07, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 05, 2022
Wednesday saw 127 companies set new 52-week lows.
Via
Benzinga
EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss
May 04, 2022
Via
Benzinga
Meet The Company Bringing New Treatments For Serious Eye Issues To Market
October 05, 2022
Sign up for this week’s All Access giveaway here!
Via
Benzinga
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
August 31, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
August 31, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
August 31, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
August 31, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
August 30, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
August 30, 2022
From
The Schall Law Firm
Via
Business Wire
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: EyePoint Pharmaceuticals Q2 Earnings
August 03, 2022
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Preview For EyePoint Pharmaceuticals
August 02, 2022
EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...
Via
Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
July 18, 2022
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
July 15, 2022
Via
Benzinga
EyePoint Announces Positive Safety and Efficacy Data From Initial-Stage Wet AMD Study
July 15, 2022
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced 12-month data readout from the Phase 1 DAVIO clinical trial evaluating EYP-1901, targeting wet age-related macular degeneration (wet AMD) as a...
Via
Benzinga
7 Wildly Oversold Nasdaq Stocks to Buy Now
July 12, 2022
For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
July 07, 2022
Upgrades
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
Recap: EyePoint Pharmaceuticals Q1 Earnings
May 04, 2022
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
EyePoint Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 28, 2022
EyePoint Pharmaceuticals (NASDAQ:EYPT) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing
March 09, 2022
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.